Hao Zheng

发表

Honokiol Crosses BBB and BCSFB, and Inhibits Brain Tumor Growth in Rat 9L Intracerebral Gliosarcoma Model and Human U251 Xenograft Glioma Model

Yuquan Wei, Xia Zhao, Cheng Peng, 2011, PloS one.

Clinical pharmacokinetics of paclitaxel liposome with a new route of administration in human based on the analysis with ultra performance liquid chromatography.

Yuquan Wei, Xianhuo Wang, Li-juan Chen, 2010, Journal of pharmaceutical sciences.

A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats.

Yuquan Wei, Xin Wei, Hao Zheng, 2010, Biochemical and biophysical research communications.

Development and validation of a UPLC-MS/MS method for quantification of SKLB010, an investigational anti-inflammatory compound, and its application to pharmacokinetic studies in beagle dogs.

Liang Ma, Ming-hai Tang, Xianhuo Wang, 2011, Journal of pharmaceutical and biomedical analysis.

(Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione protects rats from carbon tetrachloride-induced liver injury and fibrogenesis.

Yuquan Wei, Liang Ma, Hao Zheng, 2012, World journal of gastroenterology.

(Z)-5-(4-methoxybenzylidene) thiazolidine-2, 4-dione ameliorates the adjuvant-induced arthritis via inhibiting the migration of macrophage and down-regulating the cytokine mRNA expression.

Yuquan Wei, Liang Ma, Youfu Luo, 2010, International immunopharmacology.

WITHDRAWN: (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione attenuates bleomycin-induced pulmonary fibrosis in rats

Yuquan Wei, Liang Ma, Youfu Luo, 2011 .

(Z)-5-(4-Methoxybenzylidene)thiazolidine-2,4-dione, a novel readily available and orally active glitazone, attenuates the bleomycin-induced pulmonary fibrosis in vivo.

Yuquan Wei, Liang Ma, Youfu Luo, 2011, Biological & pharmaceutical bulletin.

Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases.

Yuquan Wei, Tao Chen, X. Liang, 2011, Journal of medicinal chemistry.

Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease.

Yuquan Wei, Tao Chen, Yi Ding, 2011, European journal of medicinal chemistry.

Preparation, characterization, pharmacokinetics, and bioactivity of honokiol-in-hydroxypropyl-β-cyclodextrin-in-liposome.

Yuquan Wei, Xia Zhao, Lulu Cai, 2011, Journal of pharmaceutical sciences.

Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol.

Yuquan Wei, Xia Zhao, Jiaolin Wen, 2011, International journal of pharmaceutics.

Discovery of (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice.

Yuquan Wei, Sheng-yong Yang, Gu He, 2010, Journal of medicinal chemistry.

A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance.

Mingli Xiang, Liang Ma, Li-juan Chen, 2011, European journal of pharmacology.

(Z)2‐(5‐(4‐methoxybenzylidene)‐2, 4‐dioxothiazolidin‐3‐yl) acetic acid protects rats from CCl4‐induced liver injury

Hao Zheng, Chong-yang Deng, Li-Juan Chen, 2012, Journal of gastroenterology and hepatology.